Expression of dihydropyrimidine dehydrogenase, thymidylate synthase, p53 and p21 in metastatic liver tumor from colorectal cancer after 5-fluorouracil-based chemotherapy

Anticancer Research

Volumn 25, Issue 2 B, 2005, Pages 1237-1242

  Yamagishi, Shigeru ^a,b   Shimada, Hiroshi ^a   Ishikawa, Takashi ^a   Fujii, Shouichi ^a   Tanaka, Kuniya ^a   Masui, Hidenobu ^a   Yamaguchi, Shigeki ^a   Ichikawa, Yasushi ^a   Togo, Shinji ^a   Ike, Hideyuki ^a  

^a YOKOHAMA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b YOKOHAMA CITY UNIVERSITY MEDICAL CENTER   (Japan)

Author keywords

Chemotherapy; Colorectal cancer; Gene; Liver metastasis

Indexed keywords

ANTHRACYCLINE DERIVATIVE; CISPLATIN; DIHYDROPYRIMIDINE DEHYDROGENASE; FLOXURIDINE; FLUOROURACIL; FOLINIC ACID; PROTEIN P21; PROTEIN P53; TAXANE DERIVATIVE; THYMIDYLATE SYNTHASE;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CELL VIABILITY; CHEMOSENSITIVITY; CLINICAL ARTICLE; COLORECTAL CANCER; FEMALE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOREACTIVITY; LIVER METASTASIS; MALE; PHARMACOGENETICS; PRIORITY JOURNAL;

ADULT; AGED; COLORECTAL NEOPLASMS; DIHYDROURACIL DEHYDROGENASE (NADP); FEMALE; FLUOROURACIL; HEPATIC ARTERY; HUMANS; IMMUNOHISTOCHEMISTRY; INFUSIONS, INTRA-ARTERIAL; LIVER NEOPLASMS; MALE; MIDDLE AGED; ONCOGENE PROTEIN P21(RAS); THYMIDYLATE SYNTHASE; TUMOR SUPPRESSOR PROTEIN P53;

EID: 20244367314     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Wolmark N, Wang J, Mamounas E, Bryant J and Fisher B; Preoperative chemotherapy in patients with operable breast cancer: nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18. J Natl Cancer Inst Monogr 30: 96-102, 2001.
2. World Health Organization: WHO Handbook for Reporting Results of Cancer Treatment. WHO Offset Publication No. 48. Geneva, World Health Organization, 1979.
3. Sinicrope FA, Ruan SB, Cleary KR, Stephens LC, Lee JJ and Levin B: Bcl-2 and p53 oncoprotein expression during colorectal tumorigenesis. Cancer Res 55: 237-241, 1995.
4. Heggie GD, Sommadossi JP, Cross DS, Huster WJ and Diasio RB: Clinical pharmacokinetics of 5-fluorouracil and its metabolites in plasma, urine, and bile. Cancer Res 47: 2203-2206, 1987.
5. Diasio RB: The role of dihydropyrimidine dehydrogenase (DPD) modulation in 5-FU pharmacology. Oncology 12; 23-27, 1998.
6. Johnston PG, Fisher ER, Rockette HE, Fisher B, Wolmark N, Drake JC, Chabner BA and Allegra CJ: The role of thymidylate synthase expression in prognosis and outcome of adjuvant chemotherapy in patients with rectal cancer. J Clin Oncol 12: 2640-2647, 1994.
7. Lenz HJ, Hayashi K, Salonga D, Danenberg KD, Danenberg PV, Metzger R, Banerjee D, Bertino JR, Groshen S, Leichman LP and Leichman CG: p53 point mutations and thymidylate synthase messenger RNA levels in disseminated colorectal cancer: an analysis of response and survival. Clin Cancer Res 4: 1243-1250, 1998.
8. Aschele C, Debernardis D, Casazza S, Antonelli G, Tunesi G, Baldo C, Lionetto R, Maley F and Sobrero A: Immunohistochemical quantitation of thymidylate synthase expression in colorectal cancer metastases predicts for clinical outcome to fluorouracil-based chemotherapy. J Clin Oncol 17: 1760-1770, 1999.
9. Findlay MP, Cunningham D, Morgan G, Clinton S, Hardcastle A and Aherne GW: Lack of correlation between thymidylate synthase levels in primary colorectal tumours and subsequent response to chemotherapy. Br J Cancer 75: 903-909, 1997.
10. Takeda A, Nakajima K, Shimada H, Imaseki H, Takayama W, Hayashi H, Suzuki T, Ochiai T and Isono K: Clinical significance of serum p53 antibody detection on chemosensitivity assay in human colorectal cancer. J Surg Oncol 71: 112-116, 1999.
11. Levine AJ: The p53 tumor-suppressor gene. N Engl J Med 326: 1350-1352, 1992.
12. Chang F, Syrjanen S, Tervahauta A and Syrjanen K: Tumourigenesis associated with the p53 tumour suppressor gene. Br J Cancer 68: 653-661, 1993.
13. Vogelstein B and Kinzler KW: p53 function and dysfunction. Cell 70: 523-526, 1992.
14. el-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, Lin D, Mercer WE, Kinzler KW and Vogelstein B: WAF1, a potential mediator of p53 tumor suppression. Cell 75: 817-825, 1993.
15. Hosaka N, Ichikawa Y, Ishikawa T, Nagashima Y, Kunisaki C, Takahashi M, Moriwaki Y, Akiyama H, Yamaguchi S, Ota M, Ooki S, Ike H and Shimada H: Correlation of immunohistochemical p53 labeling index with inhibition rate in chemosensitivity test in gastric and colon cancer. Anticancer Res 21: 229-235, 2001.
16. Davies MM, Johnston PG, Kaur S and Allen-Mersh TG: Colorectal liver metastasis thymidylate synthase staining correlates with response to hepatic arterial floxuridine. Clin Cancer Res 5: 325-328, 1999.
17. Nishiyama M, Yamamoto W, Park JS, Okamoto R, Hanaoka H, Takano H, Saito N, Matsukawa M, Shirasaka T and Kurihana M: Low-dose cisplatin and 5-fluorouracil in combination can repress increased gene expression of cellular resistance determinants to themselves. Clin Cancer Res 5: 2620-2628, 1999.